PMC9731151_01
Next-generation sequencing of the liquid biopsy specimen revealed a NVTAP (N486_P490) deletion. The data was provided by the Department of Research and Development, Foundation Medicine Inc.
fonc-12-976450-g001.jpg
PMC9731151_01_fonc-12-976450-g001.jpg
f1
The genomic findings revealed the mutations of BRAF NVTAP deletion ( Figure 1 ), PTEN G127R, CDKN2A/B p16INK4a V25fs*12, MUTYH splice site 892-2A>G, and TP53 R248Q.  Table 1  summarizes the tier according to ESCAT and VAF each genomic alteration.
Abdominal CT of the patient before (A, 7 July 2021) and after (B, 6 September 2021) 8 weeks of dabrafenib use.
fonc-12-976450-g002.jpg
PMC9731151_01_fonc-12-976450-g002.jpg
f2
Figure 2 ). Findings were rated as a partial response according to RECIST 1.1 criteria, and it was maintained for 6 months with continued treatment.